2018 Current Fiscal Year Report: The President's Emergency Plan for Aids Relief

Report Run Date: 06/05/2019 04:25:49 PM

1. Department or Agency 2. Fiscal Year

Department of State 2018

3. Committee or Subcommittee 3b. GSA Committee No.

The President's Emergency Plan for Aids Relief 76050

4. Is this New During Fiscal 5. Current 6. Expected Renewal 7. Expected Term

Year? Charter Date Date

No 03/13/2017 03/13/2019

8a. Was Terminated During 8b. Specific Termination 8c. Actual Term

FiscalYear? Authority Date

Public Law 92-463, Section

No 14

9. Agency Recommendation for Next10a. Legislation Req to 10b. Legislation

FiscalYear Terminate? Pending?

Continue No Not Applicable

11. Establishment Authority Agency Authority

13. 14.

12. Specific Establishment Authority Effective Committee

Presidential?

Date Type

Secretary of State and Department of State (Section

2656 of Title 22 of the United States Code)

12/05/2010Continuing No

15. Description of Committee Other Committee

16a. Total Number of No Reports for this

Reports FiscalYear

17a. Open 1 17b. Closed 0 17c. Partially Closed 0 Other Activities 0 17d. Total 1

Meetings and Dates

 Purpose
 Start
 End

 Annual Meeting
 11/09/2017
 - 11/09/2017

Number of Committee Meetings Listed: 1

	Current FY	Next FY
18a(1). Personnel Pmts to Non-Federal Members	\$0.00	\$0.00
18a(2). Personnel Pmts to Federal Members	\$0.00	\$0.00
18a(3). Personnel Pmts to Federal Staff	\$8,000.00	\$16,000.00
18a(4). Personnel Pmts to Non-Member Consultants	\$0.00	\$0.00
18b(1). Travel and Per Diem to Non-Federal Members	\$70,000.00\$	\$100,000.00
18b(2). Travel and Per Diem to Federal Members	\$0.00	\$0.00
18b(3). Travel and Per Diem to Federal Staff	\$0.00	\$0.00

 18b(4). Travel and Per Diem to Non-member Consultants
 \$0.00

 18c. Other(rents, user charges, graphics, printing, mail, etc.)
 \$2,000.00

 18d. Total
 \$80,000.00\$\$\$\$121,000.00

 19. Federal Staff Support Years (FTE)
 0.10
 0.20

20a. How does the Committee accomplish its purpose?

The Board serves the Global AIDS Coordinator ("the Coordinator") in a solely advisory capacity concerning scientific, implementation, and policy issues related to the global response to HIV/AIDS. These issues will be of concern as they influence the priorities and direction of PEPFAR evaluation and research, the content of national and international strategies and implementation, and the role of PEPFAR in the international discourse regarding appropriate and resourced responses. The committee accomplishes is purpose largely through the generation of recommendations.

20b. How does the Committee balance its membership?

The Board is composed of 29 members appointed by the Coordinator, representing non-U.S. Government personnel. All Board members are representative members. The membership is representative of the HIV/AIDS community, academia, international experts, partner government representatives, multilateral and bilateral agency representatives, foundations, advocates, and non-governmental organizations.

20c. How frequent and relevant are the Committee Meetings?

Original Estimated Number of Meetings per Year - 1 or 2 face-to-face meetings with teleconferences as needed. In order to keep committee meetings relevant and productive, working groups have been formed that meet intermittently and on an ad-hoc basis. The ideas and advice generated by the working groups result in increased productivity and clearer recommendations produced by the whole committee during face-to-face meetings.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

The committee is necessary to keep PEPFAR programs at the forefront of scientific knowledge. The members of the committee have specific expertise which is relevant and crucial to S/GAC in creating and implementing high-quality programs. The advice received by the Coordinator from the committee in the past fiscal year has assisted PEPFAR by informing next steps on how to swiftly pivot programs to achieve greater impact in response to new HIV normative guidance from the World Health Organization and others.

20e. Why is it necessary to close and/or partially closed committee meetings? N/A

21. Remarks

This committee advises S/GAC on science, implementation, and policy issues. Its function is best described as "Other" due to this broad scope. Further, this committee does not routinely produce formal reports, but does issue recommendations on policy decisions that are captured in the meeting minutes following each meeting. For a full meeting summary, including recommendations offered by the Board, please follow the link below where you may find past meeting minutes. Please see pepfar.gov/sab and pepfar.gov/sab/209264.htm.

Designated Federal Officer

Andrew Forsyth DFO

Committee Members	Start	End	Occupation	Member Designation
Abdool-Karim, Quarraisha	03/17/2017	7 03/17/2019	Associate Professor, Epidemiology, Mailman School of Public Health; Adjunct Professor, Public Health and Family Medicine, Nelson R. Mandela School of Medicine; Associate Scientific Director	Representative Member
Auerbach, Judith	03/17/2017	03/17/2019	Professor, School of Medicine, Center for AIDS Prevention Studies Professor of the Practice of Global Health	Representative Member
Berman, Peter	03/17/2017	03/17/2019	9 Systems and Economics; Director, GHP Educational Initiatives	Representative Member
Celum, Connie	03/17/2017	7 03/17/2019	Professor, Allergy and Infectious Diseases, Professor, Global Health, and Adjunct Professor, Epidemiology	Representative Member
Currier, Judith	03/17/2017	03/17/2019	Chief, Division of Infectious Diseases, Professor of Medicine, David Geffen School of Medicine	Member
Emini, Emilio	03/17/2017	03/17/2019	Director, HIV Program	Representative Member
Gruskin, Sofia	03/17/2017	7 03/17/2019	Professor of Preventive Medicine, Keck School of Medicine; Professor of Law and Preventive Medicine, Gould School of Law; Director, Program on Global Health and Human Rights, Institute for Global Health	f Representative Member
Harrington, Mark	03/17/2017	03/17/2019	Executive Director	Representative Member
Heywood, Mark	03/17/2017	03/17/2019	Executive Director	Representative Member
Kanyoro, Musimbi	03/17/2017	03/17/2019	President and CEO	Representative Member
Karita, Etienne	03/17/2017	03/17/2019	Clinician	Representative Member
Kates, Jennifer	03/17/2017	03/17/2019	Vice President and Director of Global Health and HIV Policy	Representative Member
Lockett, Lejeune	03/17/2017	03/17/2019	Operations & Program Manager, Global Health Programs	Representative Member
Macklin, Ruth	03/17/2017	03/17/2019	Albert Einstein College of Medicine, Department of Epidemiology and Population Health	Representative Member
Maxwell, Celia	03/17/2017	03/17/2019	Associate Dean for Research	Representative Member

Mayer, Kenneth	03/17/2017 03/17/2	Co-Chair and Medical Research Director; 019 Director of HIV Prevention Research; Professor of Medicine	Representative Member
Milan, Jesse	03/17/2017 03/17/2	019 Public Health and Leadership Consultant	Representative Member
Mushavi, Angela	03/17/2017 03/17/2	National PMTCT and Pediatric HIV Care and Treatment Coordinator	Representative Member
Nabiryo, Christine	03/17/2017 03/17/2	019 Director	Representative Member
Njoroge, Nyambura	03/17/2017 03/17/2	Program Executive, Ecumenical HIV and AIDS Initiatives and Advocacy	Representative Member
Pape, Jean William	03/17/2017 03/17/2	019 Professor of Meidicine; Director	Representative Member
Peters, David	03/17/2017 03/17/2	Chair and Professor, Department of International Health	al Representative Member
Redfield, Robert	03/17/2017 03/17/2	019 Associate Director / Director, Chief	Representative Member
Rio, Carlos	03/17/2017 03/17/2	Hubert Professor and Chair, Department of Global Health at the Rollins School of Public Health; Professor of Medicine, Division of Infectious Diseases	Representative Member
Sanders, Edwin	03/17/2017 03/17/2	019 Senior Servant and Founder	Representative Member
Sawe, Fredrick	03/17/2017 03/17/2	019 Senior Deputy Director	Representative Member
Siemens, Albert	03/17/2017 03/17/2	019 Chair	Representative Member
Treston, Carole	03/17/2017 03/17/2	019 Executive Director	Representative Member
Warren, Mitchell	03/17/2017 03/17/2	019 Executive Director	Representative Member
Dallabetta, Gina [HIV Prevention Continuum Working Group]		Bill & Melinda Gates Foundation	Representative Member
Kelley, Colleen [HIV Prevention Continuum Working Group]		Emory University	Representative Member

Number of Committee Members Listed: 31

Narrative Description

The Board serves the Global AIDS Coordinator ("the Coordinator") in a solely advisory capacity concerning scientific, implementation, and policy issues related to the global response to HIV/AIDS. These issues will be of concern as they influence the priorities and direction of PEPFAR evaluation and research, the content of national and international strategies and implementation, and the role of PEPFAR in the international discourse regarding appropriate and resourced responses.

What are the most significant program outcomes associated with this committee?

Checked if Applies

Trust in government Major policy changes Advance in scientific research Effective grant making Improved service delivery Increased customer satisfaction Implementation of laws or regulatory requirements Other	
Outcome Comments	
N/A	
What are the cost savings associated with this committee?	
Ch	ecked if Applies
None	✓
Unable to Determine	
Under \$100,000	
\$100,000 - \$500,000	
\$500,001 - \$1,000,000	
\$1,000,001 - \$5,000,000	
\$5,000,001 - \$10,000,000	
Over \$10,000,000	
Cost Savings Other	
Cost Savings Comments	
This is not the purpose of the committee.	
What is the approximate Number of recommendations produced by the	nis committee
for the life of the committee?	
46	

Number of Recommendations Comments

Since its inception and through the FY17 reporting period, the PEPFAR Scientific Advisory Board has issued 47 recommendations. 12 recommendations were issued to Ambassador Eric Goosby during his tenure as the U.S. Global AIDS Coordinator. 35 recommendations of the renewed Board have so far been issued to Ambassador Deborah Birx.

What is the approximate Percentage of these recommendations that have been or

will be <u>Fully</u> implemented by the agency? 54%	
% of Recommendations Fully Implemented Comments To date, approximately 55% of all recommendations have agency, and progress is being made to partially and fully in recommendations.	been fully implemented by the
What is the approximate <u>Percentage</u> of these recomme will be <u>Partially</u> implemented by the agency? 35%	endations that have been or
% of Recommendations Partially Implemented Commendation Based on the broad nature of many of the recommendation the FY17 reporting period, roughly 35% of recommendation described as partially implemented.	ns issued by the Board through
Does the agency provide the committee with feedback implement recommendations or advice offered? Yes ✓ No Not Applicable	regarding actions taken to
Agency Feedback Comments Direct communication with the board members, typically vis	a email and phone.
What other actions has the agency taken as a result of recommendation?	the committee's advice or
	Checked if Applies
Reorganized Priorities	✓
Reallocated resources	
Issued new regulation	
Proposed legislation	
Approved grants or other payments Other	
Action Comments	
N/A	

Is the Committee engaged in the review of applications for grants?

No

Grant Review Comments

N/A

How is access provided to the information for the Committee's documentation?

	Checked if Applies
Contact DFO	✓
Online Agency Web Site	✓
Online Committee Web Site	✓
Online GSA FACA Web Site	
Publications	✓
Other	

Access Comments

N/A